NRG1 Fusions in Pancreatic Cancer and Potential Role of Zenocutuzumab

Opinion
Video

The expert panel discusses NRG1 fusions in pancreatic cancer and the potential role of zenocutuzumab as a therapeutic option.

Educational support for this activity provided by Merus.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
4 experts in this video
Related Content
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 15th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 15th 2025
Podcast
Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC

Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC

Russ Conroy
August 15th 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
August 15th 2025
Podcast
Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.

Aumolertinib Has Long-Term Survival Benefit in NSCLC With Brain Metastases

Russ Conroy
August 15th 2025
Article
The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.

IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC

Tim Cortese
August 15th 2025
Article